Keyphrases
Visceral Leishmaniasis
100%
Trypanosoma Cruzi (T. cruzi)
92%
Chagas Disease
90%
Mycobacterium Tuberculosis (M. tb)
69%
Soft Drugs
60%
Sphingosine-1-phosphate Receptor (S1PR)
60%
Metabolism
57%
In Vivo Efficacy
47%
Absorption Distribution
47%
Structure-activity Relationship
39%
Preclinical Candidate
39%
Metabolic Profiling
39%
Leishmania Donovani
38%
Metabolic Stability
36%
Structure-based Design
35%
Ponesimod
33%
Esters
33%
Mouse Model
30%
Pyrazolo
30%
Mercapto
30%
Pyrimidine
30%
Accelerator Mass Spectrometry
30%
Preclinical Development
30%
Compound 8
30%
Disubstituted piperazines
30%
1,2,3-Triazole-4-carboxamide
30%
Relationship Mechanism
30%
Amino
30%
Type II NADH Dehydrogenase
30%
Absorption Mechanism
30%
Guided Synthesis
30%
Pyridazinone
30%
Morpholino
30%
Malaria
30%
Proteasome Inhibition
30%
Cryptosporidiosis
30%
Quinolones
30%
Drug Target
30%
Infectious Diseases
30%
Drug Development
30%
QcrB
30%
S1PR1
30%
Protease Inhibitors
30%
Drug Metabolism
30%
Mechanism of Action
30%
LysR Family
30%
Drug Discovery
30%
Humanized Models
30%
Thiophene
30%
5-Amino-1
30%
Pharmacology, Toxicology and Pharmaceutical Science
Visceral Leishmaniasis
100%
Trypanosoma Cruzi
92%
Chagas Disease
90%
Mycobacterium Tuberculosis
69%
Infection
67%
Proteasome
60%
Sphingosine 1 Phosphate Receptor
60%
Ponesimod
60%
Disease
56%
Mouse Model
54%
Structure Activity Relationship
45%
Oxidoreductase
45%
Pharmacokinetics
37%
Piperazine Derivative
30%
Cerlapirdine
30%
Proteasome Inhibitor
30%
Lysine Transfer RNA Ligase
30%
Amitrole
30%
Topical Agent
30%
Quinazolinone Derivative
30%
Pyrimidine Derivative
30%
Drug Development
30%
Carboxamide
30%
Side Effect
30%
Carbon 14
30%
Cryptosporidiosis
30%
Drug Discovery
30%
Drug Metabolism
30%
Drug Concentration
30%
Dermatitis
30%
Phenol
30%
Clinical Trial
22%
Protozoon
22%
Wild Type Mouse
20%
Apicomplexa
18%
Parasitosis
17%
Cryo-Electron Microscopy
17%
Leishmania donovani
15%
Esterase
15%
Aryldialkylphosphatase
15%
Cytochrome C
15%
Piperazine
15%
Thiophene
15%
Cytochrome C Oxidase
15%
Psoriasis
15%
High-Content Screening
15%
Cytotoxicity
15%
Therapeutic Window
15%
Leishmania infantum
15%
Benznidazole
15%